SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Landec Corp./CA – ‘10-K’ for 5/31/20 – ‘EX-4.1’

On:  Friday, 8/14/20, at 4:20pm ET   ·   For:  5/31/20   ·   Accession #:  1005286-20-4   ·   File #:  0-27446

Previous ‘10-K’:  ‘10-K’ on 8/1/19 for 5/26/19   ·   Next:  ‘10-K’ on 7/29/21 for 5/30/21   ·   Latest:  ‘10-K’ on 3/20/24 for 5/28/23   ·   28 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/14/20  Landec Corp./CA                   10-K        5/31/20  107:16M

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.58M 
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     36K 
 3: EX-10.39    Material Contract                                   HTML    113K 
 4: EX-21.1     Subsidiaries List                                   HTML     30K 
 5: EX-23.1     Consent of Expert or Counsel                        HTML     29K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     34K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     32K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     32K 
16: R1          Cover Page                                          HTML     93K 
17: R2          Consolidated Balance Sheets                         HTML    126K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     37K 
19: R4          Consolidated Statements of Operations               HTML    162K 
20: R5          Consolidated Statements of Comprehensive (Loss)     HTML     50K 
                Income                                                           
21: R6          Consolidated Statements of Comprehensive (Loss)     HTML     31K 
                Income (Parenthetical)                                           
22: R7          Consolidated Statements of Changes in               HTML    101K 
                Stockholders' Equity                                             
23: R8          Consolidated Statements of Cash Flows               HTML    139K 
24: R9          Organization, Basis of Presentation, and Summary    HTML    289K 
                of Significant Accounting Policies                               
25: R10         Acquisitions                                        HTML     59K 
26: R11         Investment in Non-public Company                    HTML     38K 
27: R12         Property and Equipment                              HTML     61K 
28: R13         Goodwill and Intangible Assets                      HTML    113K 
29: R14         Stock-based Compensation and Stockholders? Equity   HTML    149K 
30: R15         Debt                                                HTML     56K 
31: R16         Income Taxes                                        HTML    176K 
32: R17         Leases                                              HTML    157K 
33: R18         Commitments and Contingencies                       HTML     42K 
34: R19         Business Segment Reporting                          HTML    166K 
35: R20         Quarterly Consolidated Financial Information        HTML     91K 
                (Unaudited)                                                      
36: R21         Discontinued Operations                             HTML     76K 
37: R22         Restructuring Costs                                 HTML     59K 
38: R23         Subsequent Events                                   HTML     37K 
39: R24         Organization, Basis of Presentation, and Summary    HTML    245K 
                of Significant Accounting Policies (Policies)                    
40: R25         Organization, Basis of Presentation, and Summary    HTML    240K 
                of Significant Accounting Policies (Tables)                      
41: R26         Acquisitions (Tables)                               HTML     51K 
42: R27         Property and Equipment (Tables)                     HTML     57K 
43: R28         Goodwill and Intangible Assets (Tables)             HTML    180K 
44: R29         Stock-based Compensation and Stockholders? Equity   HTML    146K 
                (Tables)                                                         
45: R30         Debt (Tables)                                       HTML     53K 
46: R31         Income Taxes (Tables)                               HTML    171K 
47: R32         Leases (Tables)                                     HTML    120K 
48: R33         Business Segment Reporting (Tables)                 HTML    165K 
49: R34         Quarterly Consolidated Financial Information        HTML     91K 
                (Unaudited) (Tables)                                             
50: R35         Discontinued Operations (Tables)                    HTML     77K 
51: R36         Restructuring Costs (Tables)                        HTML     57K 
52: R37         Organization, Basis of Presentation, and Summary    HTML    169K 
                of Significant Accounting Policies - Narrative                   
                (Details)                                                        
53: R38         Organization, Basis of Presentation, and Summary    HTML     52K 
                of Significant Accounting Policies - Components of               
                Other Comprehensive Income (Details)                             
54: R39         Organization, Basis of Presentation, and Summary    HTML     39K 
                of Significant Accounting Policies - Allowance for               
                Sales Returns and Doubtful Accounts (Details)                    
55: R40         Organization, Basis of Presentation, and Summary    HTML     39K 
                of Significant Accounting Policies - Contract                    
                Assets and Liabilities Narrative (Details)                       
56: R41         Organization, Basis of Presentation, and Summary    HTML     57K 
                of Significant Accounting Policies -                             
                Disaggregation of Revenue (Details)                              
57: R42         Organization, Basis of Presentation, and Summary    HTML     41K 
                of Significant Accounting Policies -                             
                Reconciliation of Cash, Cash Equivalents (Details)               
58: R43         Organization, Basis of Presentation, and Summary    HTML     37K 
                of Significant Accounting Policies - Components of               
                Inventories (Details)                                            
59: R44         Organization, Basis of Presentation, and Summary    HTML     73K 
                of Significant Accounting Policies - Diluted Net                 
                Income Per Share (Details)                                       
60: R45         Organization, Basis of Presentation, and Summary    HTML     40K 
                of Significant Accounting Policies - Fair Value of               
                Contingent Consideration Liability (Details)                     
61: R46         Organization, Basis of Presentation, and Summary    HTML     50K 
                of Significant Accounting Policies - Significant                 
                Unobservable Inputs Used in Discounted Cash Flow                 
                Models (Details)                                                 
62: R47         Organization, Basis of Presentation, and Summary    HTML     38K 
                of Significant Accounting Policies - Assumptions                 
                Used in Discounted Cash Flow Models (Details)                    
63: R48         Organization, Basis of Presentation, and Summary    HTML     55K 
                of Significant Accounting Policies - Fair Value of               
                Assets and Liabilities (Details)                                 
64: R49         Organization, Basis of Presentation, and Summary    HTML     49K 
                of Significant Accounting Policies - Fair Value                  
                Reconciliation of Level 3 (Details)                              
65: R50         Acquisitions - Narrative (Details)                  HTML    120K 
66: R51         Acquisitions - Schedule of Business Acquisitions    HTML     37K 
                (Details)                                                        
67: R52         Acquisitions - Schedule of Purchase Price           HTML     71K 
                Allocation (Details)                                             
68: R53         Investment in Non-public Company (Details)          HTML     78K 
69: R54         Property and Equipment - Components of Property     HTML     63K 
                and Equipment (Details)                                          
70: R55         Property and Equipment - Narrative (Details)        HTML     65K 
71: R56         Goodwill and Intangible Assets - Changes in         HTML     39K 
                Goodwill (Details)                                               
72: R57         Goodwill and Intangible Assets - Narrative          HTML     73K 
                (Details)                                                        
73: R58         Goodwill and Intangible Assets - Other Intangible   HTML     63K 
                Assets (Details)                                                 
74: R59         Stock-based Compensation and Stockholders? Equity   HTML     79K 
                - Narrative (Details)                                            
75: R60         Stock-based Compensation and Stockholders? Equity   HTML     52K 
                - Weighted Average Assumptions (Details)                         
76: R61         Stock-based Compensation and Stockholders? Equity   HTML     75K 
                - Stock Options Outstanding and Exercisable                      
                (Details)                                                        
77: R62         Stock-based Compensation and Stockholders? Equity   HTML     53K 
                - Stock-based Compensation Activity (Details)                    
78: R63         Stock-based Compensation and Stockholders? Equity   HTML     39K 
                - Summary of Stock-based Compensation by Income                  
                Statement Line Item (Details)                                    
79: R64         Debt - Narrative (Details)                          HTML    119K 
80: R65         Debt - Long-term Debt (Details)                     HTML     44K 
81: R66         Debt - Future Minimum Principal Payments of Debt    HTML     37K 
                (Details)                                                        
82: R67         Income Taxes - Narrative (Details)                  HTML     70K 
83: R68         Income Taxes - Provision for Income Taxes           HTML     54K 
                (Details)                                                        
84: R69         Income Taxes - Income Tax Rate Reconciliation       HTML     57K 
                (Details)                                                        
85: R70         Income Taxes - Deferred Tax Assets and Liabilities  HTML     68K 
                (Details)                                                        
86: R71         Income Taxes - Unrecognized Tax Benefits (Details)  HTML     43K 
87: R72         Leases - Narrative (Details)                        HTML     63K 
88: R73         Leases - Schedule of Lease Costs (Details)          HTML     54K 
89: R74         Leases - Maturity Analysis of Operating and         HTML    100K 
                Finance Lease Liabilities (Details)                              
90: R75         Leases - Future Minimum Annual Lease Payments       HTML     46K 
                Under Operating Leases (Details)                                 
91: R76         Leases - Future Minimum Annual Lease Payments       HTML     54K 
                Under Capital Lease (Details)                                    
92: R77         Leases - Supplemental Cash Flow Information         HTML     39K 
                (Details)                                                        
93: R78         Commitments and Contingencies (Details)             HTML     57K 
94: R79         Business Segment Reporting - Narrative (Details)    HTML     33K 
95: R80         Business Segment Reporting - Property and           HTML     36K 
                Equipment, Net by Geographic Region (Details)                    
96: R81         Business Segment Reporting - Sales by Geographic    HTML     47K 
                Area (Details)                                                   
97: R82         Business Segment Reporting - Operations by          HTML     93K 
                Business Segment (Details)                                       
98: R83         Quarterly Consolidated Financial Information        HTML     67K 
                (Unaudited) (Details)                                            
99: R84         Discontinued Operations - Assets and Liabilities    HTML     87K 
                of Discontinued Operations (Details)                             
100: R85         Discontinued Operations - Narrative (Details)       HTML     37K  
101: R86         Restructuring Costs - Narrative (Details)           HTML     46K  
102: R87         Restructuring Costs - Schedule of Costs (Details)   HTML     56K  
103: R88         Subsequent Events (Details)                         HTML     68K  
105: XML         IDEA XML File -- Filing Summary                      XML    194K  
15: XML         XBRL Instance -- lndc-20200531_htm                   XML   4.41M 
104: EXCEL       IDEA Workbook of Financial Reports                  XLSX    153K  
11: EX-101.CAL  XBRL Calculations -- lndc-20200531_cal               XML    439K 
12: EX-101.DEF  XBRL Definitions -- lndc-20200531_def                XML   1.06M 
13: EX-101.LAB  XBRL Labels -- lndc-20200531_lab                     XML   2.65M 
14: EX-101.PRE  XBRL Presentations -- lndc-20200531_pre              XML   1.66M 
10: EX-101.SCH  XBRL Schema -- lndc-20200531                         XSD    229K 
106: JSON        XBRL Instance as JSON Data -- MetaLinks              597±   895K  
107: ZIP         XBRL Zipped Folder -- 0001005286-20-000004-xbrl      Zip    553K  


‘EX-4.1’   —   Instrument Defining the Rights of Security Holders


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

Exhibit 4.1

DESCRIPTION OF CAPITAL STOCK
The following description of the capital stock of Landec Corporation (the “Company,” “we,” “us,” and “our”) is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our certificate of incorporation, which has been publicly filed with the Securities and Exchange Commission.
Our authorized capital stock consists of:
50,000,000 shares of common stock, $0.001 par value; and
2,000,000 shares of preferred stock, $0.001 par value.
Common Stock
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. In any election of directors, a director nominee shall be elected if the votes cast for such nominee’s election exceed the votes cast against such nominee’s election (with abstentions not counted as a vote cast either for or against that nominee’s election) by the stockholders entitled to vote on the election. Any director or our entire board of directors (the “Board”) may be removed, with or without cause, and any vacancies on the Board may be filled, by the holders of a majority of the shares then entitled to vote at an election of directors. Amendments to our bylaws may be adopted by the affirmative vote of a majority in voting power of all of the then outstanding shares of the voting stock of the Company entitled to vote. All other matters shall be decided by the affirmative vote of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at a meeting by the holders entitled to vote thereon.
Holders of common stock are entitled to receive proportionately any dividends as may be declared by our Board, subject to any preferential dividend rights of outstanding preferred stock.
In the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled to receive proportionately our net assets available after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.
Classified Board
In accordance with the terms of our certificate of incorporation and bylaws, subject to the rights of holders of any series of preferred stock to elect directors, our Board is divided into two classes: Class 1 and Class 2, with each class serving staggered two-year terms. This classification of the Board may have the effect of delaying or preventing changes in the control or management of the Company.
Preferred Stock
Under the terms of our certificate of incorporation, our Board is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our Board has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock. We have designated one series of preferred stock.
1


The purpose of authorizing our Board to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.
The preferred stock of each series will rank senior to the common stock in priority of payment of dividends and in the distribution of assets in the event of our liquidation, dissolution or winding up, to the extent of the preferential amounts to which the preferred stock of the respective series will be entitled. Upon issuance, the shares of preferred stock will be fully paid and nonassessable, which means that its holders will have paid their purchase price in full and we may not require them to pay additional funds.
Anti-Takeover Effects of Delaware Law and Our Charter and Bylaws
In our certificate of incorporation, we elect not to be subject to Section 203 of the General Corporation Law of the State of Delaware. Subject to certain exceptions, Section 203 prevents a publicly-held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for three years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our Board or unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger or consolidation involving us, and the interested stockholder and the sale of more than 10% of our assets. In general, an “interested stockholder” is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.
Our certificate of incorporation provides that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our bylaws provide that special meetings of the stockholders can be called by the Board, the Chairman of the Board, the president or by one or more stockholders holding shares in the aggregate entitled to cast not less than 10% of the votes at that meeting. In addition, our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our Board. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our Board or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder’s intention to bring such business before the meeting. These provisions could have the effect of delaying certain stockholder actions until the next stockholder meeting.
2

6 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/20/24  Lifecore Biomedical, Inc./DE      10-K        5/28/23  138:75M
 6/06/23  Lifecore Biomedical, Inc./DE      S-1/A                  2:365K                                   Workiva Inc Wde… FA01/FA
 4/06/23  Lifecore Biomedical, Inc./DE      S-1                    4:527K                                   Workiva Inc Wde… FA01/FA
 3/16/23  Lifecore Biomedical, Inc./DE      10-K/A      5/29/22  129:20M
 9/14/22  Lifecore Biomedical, Inc./DE      10-K        5/29/22  112:17M
 7/29/21  Lifecore Biomedical, Inc./DE      10-K        5/30/21  107:13M


22 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/17/20  Lifecore Biomedical, Inc./DE      8-K:1,2,7,9 7/15/20    3:131K                                   Workiva Inc Wde… FA01/FA
 3/25/20  Lifecore Biomedical, Inc./DE      8-K:1,2,5,8 3/19/20    3:3.5M                                   Workiva Inc Wde… FA01/FA
10/30/19  Lifecore Biomedical, Inc./DE      8-K:2,8,9  10/25/19    3:202K                                   Workiva Inc Wde… FA01/FA
10/21/19  Lifecore Biomedical, Inc./DE      8-K:5,9    10/15/19    2:376K                                   Workiva Inc Wde… FA01/FA
 5/24/19  Lifecore Biomedical, Inc./DE      8-K:5,9     5/24/19    2:39K                                    Workiva Inc Wde… FA01/FA
 5/07/19  Lifecore Biomedical, Inc./DE      8-K:5,9     5/06/19    2:39K                                    Workiva Inc Wde… FA01/FA
 2/05/19  Lifecore Biomedical, Inc./DE      8-K:5,9     2/05/19    3:290K                                   Workiva Inc Wde… FA01/FA
12/06/18  Lifecore Biomedical, Inc./DE      8-K:1,2,8,911/30/18    4:3.2M                                   RDG Filings/FA
10/17/18  Lifecore Biomedical, Inc./DE      8-K:1,5    10/10/18    2:111K                                   RDG Filings/FA
 7/30/18  Lifecore Biomedical, Inc./DE      8-K:5       7/25/18    1:21K                                    RDG Filings/FA
 5/25/18  Lifecore Biomedical, Inc./DE      8-K:1,5,8,9 5/22/18    3:111K                                   RDG Filings/FA
 5/02/18  Lifecore Biomedical, Inc./DE      8-K:1,9     4/26/18    2:107K                                   RDG Filings/FA
10/23/17  Lifecore Biomedical, Inc./DE      8-K:5,9    10/19/17    2:64K                                    RDG Filings/FA
 7/24/17  Lifecore Biomedical, Inc./DE      8-K:5       7/19/17    1:18K                                    RDG Filings/FA
 5/10/17  Lifecore Biomedical, Inc./DE      8-K:1,9     5/05/17    2:325K                                   RDG Filings/FA
 9/29/16  Lifecore Biomedical, Inc./DE      8-K:2,9     9/23/16    5:8.7M                                   RDG Filings/FA
 3/03/16  Lifecore Biomedical, Inc./DE      8-K:1,2,9   2/26/16    5:581K                                   RDG Filings/FA
10/11/13  Landec Corp./CA                   8-K:5,9    10/10/13    2:336K                                   RDG Filings/FA
 7/31/13  Landec Corp./CA                   8-K:5       7/25/13    1:27K                                    RDG Filings/FA
10/16/12  Landec Corp./CA                   8-K:5,9    10/11/12    2:208K                                   RDG Filings/FA
10/19/09  Landec Corp./CA                   8-K:1,9    10/15/09    6:409K                                   Toppan Merrill/FA
11/07/08  Landec Corp./CA                   8-K:1,3,8,911/06/08    5:147K                                   Business Wire/FA
Top
Filing Submission 0001005286-20-000004   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 6:10:52.2pm ET